GlassScriptPhysician profile
Seth M Zeidman
NPI 1902911704
$338,461.19
in general payments reported to CMS, 2019-2025
30 companies · $44K in 2025
The $44K reported for 2025 was more than what 94% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68K · 2020: $38K · 2021: $72K · 2022: $42K · 2023: $41K · 2024: $32K · 2025: $44K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $113K · Food and Beverage: $4,919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $113,105.81 |
| Food and Beverage | $4,918.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $292,714.28 | 2019-2025 | Independence Mis, Independence, Independence |
| Medtronic, INC. | $22,906.70 | 2021-2025 | Intellis Adaptivestim, Atlantis Anterior Cervical Plate System, Pivox Oblique Lateral Spinal System |
| Medtronic USA, INC. | $14,933.61 | 2019 | |
| Abbott Laboratories | $1,414.31 | 2022-2025 | Proclaim, Eterna |
| Cerapedics INC. | $1,391.40 | 2020-2024 | I-Factor Peptide Enhanced Bone Graft |
| Boston Scientific Corporation | $1,146.06 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Nevro Corp. | $920.41 | 2019-2024 | Senza |
| Providence Medical Technology, INC. | $750.51 | 2024-2025 | |
| Abbvie INC. | $365.95 | 2022-2025 | Ubrelvy, Botox |
| Depuy Synthes Sales INC. | $335.86 | 2019-2025 | Conduit, Teligen, Aegis |
| Intrinsic Therapeutics | $320.29 | 2023 | Barricaid Acd (Annular Closure Device) |
| Saluda Medical Americas, INC. | $228.66 | 2024-2025 | Evoke |
| Nexxt Spine LLC | $203.92 | 2021 | |
| Prosidyan, INC | $182.50 | 2019 | |
| Clariance, INC. | $122.21 | 2022-2023 | Idys-Alif |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Djo, LLC | $106.22 | 2019 | |
| Augmedics INC. | $68.74 | 2022-2024 | Xvision |
| Smith+Nephew, INC. | $59.60 | 2024-2025 | Pico |
| Baxter Healthcare | $45.33 | 2025 | Floseal |
| Spr Therapeutics, INC | $39.12 | 2024-2025 | Sprint Pns System |
| Scilex Pharmaceuticals INC. | $36.45 | 2020 | |
| Si-Bone, INC. | $32.80 | 2022-2023 | |
| Conmed Corporation | $25.96 | 2020 | |
| Lilly USA, LLC | $21.71 | 2023 | Reyvow, Emgality |
| Sanara Medtech INC. | $21.43 | 2025 | Celleraterx |
| Theragen, INC. | $18.75 | 2023 | Actastim-S |
| Bioventus LLC | $17.50 | 2025 | Bonescalpel & Sonicone (O.R.) |
| Aesculap, INC. | $17.28 | 2024 | Aesculap |
| Ebi, LLC | $13.63 | 2025 | Biomet Spinalpak Non-Invasive Spine Fusion Stimulator System |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$58,125.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Zeidman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.